Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CHIMERIC MONOCLONAL CD-20 ANTIBODY (RITUXIMAB) FOR STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR-AGVHD): A PILOT STUDY

NCT00578591 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT00578591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00578591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CHIMERIC MONOCLONAL CD-20 ANTIBODY (RITUXIMAB) FOR STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR-AGVHD): A PILOT STUDY
Lead sponsor
Baylor College of Medicine
Phase
Phase 2
Overall status
Withdrawn
Start date
June 30, 2007
Completion date
Not reported
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alogenic hematopoietic transplant, graft vs host disease